Jesper Bramming, former A.P. Moller Executive, Joins the CMC Biologics Executive Management Team as Chief Financial Officer

COPENHAGEN, Denmark and SEATTLE, Jan. 8, 2014 /PRNewswire/ -- CMC Biologics, a leading biopharmaceutical process development and biopharmaceutical manufacturing organization, announced today that it has appointed Jesper Bramming as Chief Financial Officer (CFO) of its global operations.

(Logo: http://photos.prnewswire.com/prnh/20110502/SF93356LOGO)

Jesper Bramming brings more than 25 years of financial and management experience to CMC Biologics' Executive Management Team, including 9 years as CFO at financial service provider Nets Holding and in two subsidiaries in A. P. Moller – Maersk Group: Maersk Oil & Gas and Svitzer.

Mr. Bramming has previously held international management positions as an equity portfolio manager and financial analyst at A. P. Moller Maersk and within the banking industry. He holds a Master of Economics from the University of Copenhagen and has completed executive education programs at Columbia University, including the Columbia Senior Executive Program.

"We're very pleased to welcome Jesper to our global executive team managing financial operations in both Copenhagen and North American. The breadth of his international finance and financial services expertise is impressive, and we expect him to play a key role in preparing CMC Biologics for its next phase of success," said Claes Glassell, Chief Executive Officer of CMC Biologics.

"CMC Biologics has outstanding process development and manufacturing expertise to serve sophisticated clinical and commercial biopharmaceutical markets," said Jesper Bramming. "I am excited to join the company as it embarks on a new level of growth and I look forward to contributing to the team's execution of its development plan."

About CMC Biologics
CMC Biologics is committed to delivering world class biopharmaceutical process development and manufacturing services, specializing in custom services for scale up and cGMP manufacture of protein-based therapeutics for preclinical, clinical trials, and commercial production. The Company's fully integrated services includes cell line development using its proprietary CHEF1® system, process and formulation development, and comprehensive analytical testing. CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers stirred tank and perfusion production processes. To learn more, visit www.cmcbiologics.com.

Media Contacts:
Stacie D. Byars
CMC Biologics Global Marketing
sbyars@cmcbio.com
+1 (206) 660-2588